RLAY
HealthcareRelay Therapeutics, Inc.
$7.86
$-0.32 (-3.91%)
Jan 5, 2026
Price History (1Y)
Analysis
Relay Therapeutics, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $1.36 billion and 188 employees. It operates in the industry of biotechnology. The company's financial health indicates significant losses, with net income totaling -$297,592,992 and EBITDA at -$320,495,008 over the trailing twelve months. Profit margins are at 0.0%, while operating margin is -3887.3%. Return on equity stands at -41.1% and return on assets at -25.4%. The balance sheet reveals $596.43 million in cash and $33.33 million in debt, resulting in a debt-to-equity ratio of 5.48. Valuation metrics show a forward P/E of -4.89, price to book of 2.23, and price to sales of 163.05. The company's valuation is further characterized by an EV/EBITDA ratio of -2.67, indicating significant losses in relation to enterprise value.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.36B
- P/E Ratio
- N/A
- 52-Week High
- $9.04
- 52-Week Low
- $1.77
- Avg Volume
- 2.18M
- Beta
- 1.55
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 188